China-entry partner for a Euronext listed medtec company

WISER helps a Frech medtech company enters China with local establishment

Client Background

A France-based medical imaging technology company founded in 2002, listed on Euronext Growth. The company provides innovative AI-powered imaging solutions for oncology trials and precision medicine. Its shareholder structure reflects a global reach, with major investors from China, the USA, Japan, and Europe.

The Challenge

China's healthcare market is undergoing rapid digitalization, with strong government support for AI-assisted diagnostics and precision medicine. The company already had Chinese shareholders, signaling existing market interest. However, it lacked the local operational capability to translate this interest into commercial traction — including regulatory approvals, hospital partnerships, and clinical validation in the Chinese healthcare system.

Our Role

We perfom as the China-entry partner, as well as financial advisor for acquiring local strategic investors.

Our Approach

WISER provided China-entry advisory with a focus on local establishment. Services included regulatory pathway analysis for medical AI software, identification of hospital and clinical research partners, local entity setup guidance, and go-to-market strategy tailored to China's tiered healthcare system.

Results

- Local entity established in China
- Regulatory roadmap defined for the Chinese market
- Initial hospital and clinical research partnerships identified